Distinguishing neurocognitive deficits in adult patients with NP-C from early onset Alzheimer ’s dementia

Niemann-Pick disease type C (NP-C) is a rare, progressive neurodegenerative disease caused by mutations in the NPC1 or the NPC2 gene. Neurocognitive deficits are common in NP-C, particularly in patients with the ...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Tags: Research Source Type: research

Related Links:

Today's open access paper outlines an investigation into how the aging of hematopoietic stem cell populations in bone marrow, responsible for producing blood and immune cells, can contribute to age-related dysfunction in the brain. The authors find that detrimental effects are mediated by circulating levels of CyPA, a signaling factor that is a part of the senescence-associated secretory phenotype (SASP), an inflammatory mix of signal molecules produced by senescent cells. The focus here is on direct inhibition of CyPA as an approach to therapy, but senolytic treatments to clear senescent cells may be the more useful appro...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Drs Ronald Petersen and John Morris discuss the effects of COVID-19 on Alzheimer's research and drug trials.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Authors: Disoteo OE, Zampetti B, Garascia A, Attanasio R, Cozzi R Abstract A 24-yo female was admitted for acute renal failure, melanoderma, hyponatremia and hyperkalemia. The clinical suspicion of Addison's disease was confirmed by laboratory test and the appropriate replacement therapy with corticosteroids and fludrocortisone was started. In the mean-time primary hypothyroidism and diabetes mellitus type 1 were disclosed and treated, thus fulfilling a diagnosis of autoimmune polyendocrine syndrome type 2. Eighteen months later she was admitted for right sided heart failure. The work-up allowed to diagnose pulmona...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Diagnosis of the behavioral variant of frontotemporal dementia remains challenging. This review presents clinical recommendations for differentiating bvFTD from primary psychiatric disorders.Brain
Source: Medscape Radiology Headlines - Category: Radiology Tags: Neurology & Neurosurgery Journal Article Source Type: news
TUESDAY, Aug. 4, 2020 -- Repetitive negative thinking (RNT) may be associated with increased Alzheimer disease (AD) risk, according to a study published in the July issue of Alzheimer's&Dementia. Natalie L. Marchant, Ph.D., from University...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
  What does psychosis feel like? What’s the difference between a delusion that demons exist and a religious belief of the same? In today’s show, Gabe and Lisa recall Gabe’s real-life psychotic episodes and discuss all the pain and stress surrounding psychosis. Join us as Gabe shares how it felt when there were demons under his bed and when the window washers were watching his every move. (Transcript Available Below) Please Subscribe to Our Show: And We Love Written Reviews!  About The Not Crazy podcast Hosts Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Bipolar General Not Crazy Podcast Schizophrenia Source Type: blogs
Presently available methods of determining whether or not amyloid-β aggregates exist in the brain are expensive and invasive. Amyloid-β forms solid deposits in and around cells in the brain for decades prior to the first obvious signs of neurodegeneration, and people with raised levels of these protein aggregates are more likely to progress to dementia. Early, accurate, low-cost measurements of amyloid-β prior to symptoms could lead to the identification of lifestyle choices that minimize risk, as well as to the development of preventative therapies. Absent assays that can achieve this goal, there is little ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(Salk Institute) A drug candidate developed by Salk researchers, and previously shown to slow aging in brain cells, successfully reversed memory loss in a mouse model of inherited Alzheimer's disease. The new research, published online in July 2020 in the journal Redox Biology, also revealed that the drug, CMS121, works by changing how brain cells metabolize fatty molecules known as lipids.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Source: BMJ News - Category: General Medicine Source Type: research
Date: Wednesday, 09 09, 2020; Speaker: Sigrid Veasey, MD , Sleep Neuroscience and Dementia , University of Pennsylvania; Ruth Benca, MD, PhD , Psychiatry and Sleep , University of California, Irvine; Azizi Seixas, PhD , Big Data and Sleep , New York University Langone Health; Michael Twery, PhD (Moderator), Live Q&A, NHLBI National Center on Sleep Disorders Research; videocast.nih.gov; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Alzheimer's | Brain | Dementia | Genetics | Internal Medicine | Neurology | Niemann-Pick Disease | Rare Diseases